Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Mol Clin Oncol
2016 Feb 01;42:195-200. doi: 10.3892/mco.2015.690.
Show Gene links
Show Anatomy links
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Furukawa M
,
Toyooka S
,
Ichimura K
,
Yamamoto H
,
Soh J
,
Hashida S
,
Ouchida M
,
Shien K
,
Asano H
,
Tsukuda K
,
Miyoshi S
.
???displayArticle.abstract???
Pulmonary adenocarcinoma (PA) with a micropapillary component (PA-MPC) is known as an aggressive subtype of PA. The molecular profiles of PA-MPC have not been well characterized. the pathological reports of patients who underwent surgical resection for lung cancer between April, 2004 and May, 2012 were reviewed. Of the 674 patients diagnosed with PA, 28 were found to have MPC. A total of 138 resected PAs without MPC were selected in the same period to serve as age-, gender- and smoking status-matched controls to the PA-MPC group. Mutational status was determined by the following two methods: SNaPshot assay based on multiplex polymerase chain reaction (PCR), primer extension and capillary electrophoresis that was designed to assess 38 somatic mutations in 8 genes [AKT1, BRAF, endothelial growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), mitogen-activated protein kinase kinase 1, neuroblastoma RAS viral oncogene homolog, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α (PIK3CA) and phosphatase and tensin homolog]; and a PCR-based sizing assay that assesses EGFR exon 19 (deletions), EGFR exon 20 (insertions) and human epidermal growth factor receptor 2 exon 20 (insertions). echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene (EML4-ALK) was screened by ALK immunohistochemistry and confirmed using the reverse transcription PCR assay and the break-apart fluorescence in situ hybridization assay. Regarding genetic alterations, 13 (46.4%) of the 28 PA-MPCs harbored mutually exclusive mutations: 9 (32.1%) EGFR mutations, 1 (3.6%) KRAS mutation and 3 (10.7%) EML4-ALK fusion genes. PAs without MPC harbored 42 (30.4%) EGFR mutations, 17 (12.3%) KRAS mutations, 3 (2.2%) EML4-ALK fusion genes and 1 (0.7%) PIK3CA mutation. EML4-ALK fusion genes appeared to occur significantly more frequently in PA-MPCs compared with PAs without MPC (P=0.027). Although the sample size was small, our study suggests that the molecular pathogenesis of PA-MPC may be different from that of other adenocarcinomas.
Amin,
Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance.
2002, Pubmed
Amin,
Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance.
2002,
Pubmed
Asano,
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.
2006,
Pubmed
Barlesi,
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
2014,
Pubmed
Cadranel,
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
2012,
Pubmed
De Oliveira Duarte Achcar,
Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
2009,
Pubmed
Inamura,
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
2009,
Pubmed
,
Echinobase
Jokoji,
Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.
2010,
Pubmed
,
Echinobase
Katanoda,
An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013.
2015,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Makimoto,
Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours).
2005,
Pubmed
Malvezzi,
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?
2015,
Pubmed
Mitsudomi,
Advances in target therapy for lung cancer.
2010,
Pubmed
Miyoshi,
Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis.
2003,
Pubmed
Motoi,
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
2008,
Pubmed
Ninomiya,
Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.
2009,
Pubmed
Paik,
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
2011,
Pubmed
Rodig,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
2009,
Pubmed
Roh,
Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma.
2004,
Pubmed
Shigematsu,
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
2005,
Pubmed
Siegel,
Cancer statistics, 2015.
2015,
Pubmed
Su,
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
2011,
Pubmed
Sánchez-Mora,
Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series.
2008,
Pubmed
Takeuchi,
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
2008,
Pubmed
Tokumo,
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
2006,
Pubmed
Tokumo,
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
2005,
Pubmed
Toyooka,
The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.
2007,
Pubmed
Toyooka,
Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR.
2003,
Pubmed
Travis,
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
2011,
Pubmed
Yoshida,
Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
2011,
Pubmed
Yoshizawa,
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.
2011,
Pubmed
